MedTrace Logo

Monitoring Minimal Residual Disease（MRD）in Pediatric B-acute Lymphoblastic Leukemia

NCT04977895 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 255

Last updated 2021-07-27

No results posted yet for this study

Summary

This study aimed to investigate the performance of next-generation sequencing (NGS) techniques measuring immunoglobulin heavy chain (IgH)-variable, diversity, and joining (V\[D\]J) clonal rearrangements （IgH-V\[D\]J NGS） compared with flow cytometry (FCM) in detecting of minimal residual disease (MRD) for children with acute lymphoblastic leukemia treated with South Chinese Children Leukemia Group (SCCLG)-ALL 2016, and to predict the relapse of the disease in the early stage and to assess the prognosis, so as to provide the basis for early intervention treatment and reduce the hematological relapse and improve the survival rate.

Conditions

  • B Acute Lymphoblastic Leukemia

Interventions

DIAGNOSTIC_TEST

Minimal residual disease (MRD) monitoring

Minimal residual disease (MRD) assay using IgH-V(D)J NGS and FCM

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Yi-Zhuo Zhang, MD · Sun Yat-sen University

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-30
Primary Completion
2024-01-30
Completion
2026-01-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04977895 on ClinicalTrials.gov